Largest Psychedelic Stocks -3.4% In March

TM Editors Note: This article mentions one or more penny stocks/microcaps. Such stocks are easily manipulated; do your own careful due diligence.

According to a study by Data Bridge Market Research, the global market for psychedelics is growing and will reach a value of over $6 billion within the next five years, compared to $2 billion in 2019. This represents a compound annual growth rate of over 16% for the industry.

The 7 largest psychedelic drug stocks (market caps of $75M or more) tracked in our munKNEE Psychedelic Drug Stocks index are ranked below, in descending order, as to:

  • their stock performances in March and year-to-date (YTD),
  • their likelihood of Financial Distress within the next 2 years according to data from macroaxis.com, and
  • their average 12-month Price Targets,
  • the extent of Short Interest and
  • the degree of Insider Ownership (all as sourced from SeekingAlpha.com) and
  • their current Market Capitalization.
  1. Compass Pathways (CMPS): UP 7.4% in March; UP 27.1% YTD
    • 12 analysts have:
      • an average year-end price target representing a 318% increase from its March 31st price and
      • a consensus BUY rating,
    • has a 30% Chance of Financial Distress within 2 years;
    • a Short Interest of 34.0% (the number of shorted shares divided by the number of shares outstanding),
    • a 42.3% Insider Ownership (directors and senior officers or other beneficial holders with 10% or more of the common shares),
    • a current Market Capitalization of $371M and
    • is primarily focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
    • Read: Compass Pathways - Entering A Brave New World
  2. Incannex Healthcare (IXHL): UP 14.5% in March; DOWN 22.1% YTD
    • Incannex engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies and has the largest portfolio of such products an therapies worldwide with a potential global addressable market for all Incannex' products under development exceeds $400B per annum.
    • Incannex has a current Market Capitalization of $132M.
    • Incannex is a new addition to this index and is not covered by any Wall Street analysts.
    • The Company is headquartered in Australia and trades on the Australian Stock Exchange (ASX) and the Nasdaq.
    • Read: Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products
  3. Atai (ATAI): UP 7.7% in March; DOWN 29.8% YTD
    • 14 analysts have:
      • an average year-end price target representing a 556% increase from its March 31st price,
      • a consensus BUY rating;
    • has a 7% Chance of Financial Distress within 2 years,
    • a Short Interest of 3.1%,
    • only a 0.39% in Insider Ownership,
    • a current Market Capitalization of $207M and
    • is primarily focused on the use of ketamine*, DMT* and ibogaine*.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
    • Read: Atai Life Sciences: Long On Money; Short On Success
  4. Seelos (SEEL): DOWN 12.7%; UP 6.2% YTD
    • 4 analysts have:
      • an average year-end price target  representing a 661% increase from its March 31st price,
      • a consensus BUY rating and
    • has a 61% Chance of Financial Distress within 2 years,
    • a Short Interest of 5.7%,
    • a 2.83% Insider Ownership,
    • a current Market Capitalization of $80M and
    • is primarily focused on the use of ketamine*. Go here for much more extensive information on Ketamine.
    • Read: Seelos Addressing Significant And Unmet Needs In Rare Psychiatric And Movement Disorders
  5. Mind Medicine (MNMD): DOWN 14.7%; UP 48.8% YTD 
    • 8 analysts have:
      • an average year-end price target of representing a 614% increase from the March 31st price,
      • a consensus BUY rating and
    • has a 54% Chance of Financial Distress within 2 years,
    • a Short Interest of 8.9%,
    • an 11.1% Insider Ownership,
    • a current Market Capitalization of $110M and
    • is primarily focused on the use of LSD* and MNMA*. Go here for much more extensive information on LSD and  here for much more extensive information on MDMA.
    • Read: MindMed: Researching LSD And MNMA To Treat Neurological Diseases
  6. GH Research (GHRS): DOWN 16.6% in March; DOWN 16.2% YTD
    • 6 analysts have:
      • an average year-end price target representing a 376% increase from the March 31st price and
      • a consensus BUY rating,
    • has a 58% Chance of Financial Distress within 2 years,
    • a Short Interest of 7.9%,
    • a 40.4% Insider Ownership,
    • a current Market Capitalization of $425M and
    • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine but is better known by its nick name, “The Toad”,
    • Read: GH Resources: Focus On Treatment-Resistant Depression Paying Off 
  7. Cybin (CYBN): DOWN 25.0%; UP 34.5% YTD
    • 5 analysts have:
      • an average year-end price target representing a 1356% increase from its March 31st price,
      • a consensus BUY rating and
    • has a 58% Chance of Financial Distress within 2 years,
    • a Short Interest of 1.9%,
    • a 21.4% Insider Ownership,
    • a current Market Capitalization of $77M and
    • is primarily focused on the use of DMT* and Psilocybin*. Go here for much more extensive information on DMT and here for much more extensive information on Psilocybin.
    • Read: Cybin Inc. Was Down 70% In 2022 But Has Bounced Back By 59% YTD - Here's Why

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.

In summary:

  • the munKNEE Psychedelic Drug Stocks Index:
    • was DOWN 3.4% in March but is still UP 1.2% YTD
  • the average price targets of the above stocks represent an average 372% increase from their March 31st closes.

If you are interested in this category of clinical-stage psychedelic compound-based stocks consider the AdvisorShares Psychedelic ETF (PSIL) that consists of 23 such stocks but keep in mind that the vast majority have market capitalizations of $50M or less (i.e. are nano-caps). It was DOWN 11.3% in March but is still UP 1.1% YTD as compared to the munKNEE Psychedelic Drug Stocks Index featured above.


More By This Author:

March Recap: Largest Plant-Based Food Stocks
March Recap: Largest Canadian Cannabis LPs Down 13.5%
Columbia Care Q4 Financials Unimpressive: Analysts Remain Optimistic

Disclosure: None

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.